Bayer, Nuvisan to open small molecule research center

By Jenni Spinner

- Last updated on GMT

(Image: Getty/Gorodenkoff)
(Image: Getty/Gorodenkoff)
The firms are joining forces to establish a specialized research unit in Berlin.

Bayer plans to shift a significant portion of its Berlin-based small molecule research activity to Nuvisan. The latter company provides clinical study, laboratory and contract manufacturing services.

Joerg Moeller, head of research and development for Bayer AG’s Pharmaceuticals Division and member of its executive committee, said the firm hopes to build a “strong, full-fledged research unit​” with Nuvisan.

Nuvisan shares our vision that the new research center can become an important player in research partnering based on the joint know-how and capabilities of our highly qualified scientists​,” Moeller said.

The new research entity housed at the center reportedly will create 400 jobs in the area. Capabilities across the drug discovery chain include lead discovery, medicinal chemistry, pharmacology, drug metabolism and pharmacokinetics, investigational toxicology, and animal management.

Dietrich Bruchmann, Nuvisan CEO and managing partner, said the capabilities of the German facility will empower a “high-performance research team​” by offering access to specialized technology.

The acquisition of the research unit and its location at the Bayer R&D campus will create an operational hub in the scientific excellence cluster in Berlin and allow us to significantly accelerate the drug development process from discovery to clinical trials​,” Bruchmann said.

According to Bayer, the partnership will enable the company to focus its efforts on R&D flexibility and productivity. Bayer intends to continue additional research activities and corporate functions at its Berlin-based Pharmaceuticals Division.

The arrangement marks the latest in a series of partnerships Bayer has formed with other entities in the past few months. In late January 2020, the firm inked a five-year deal with Schrodinger​ to develop molecule-design software. A few weeks earlier, Bayer expanded its work with Evotec​ on developing women’s health drugs.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars